Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young Adults

Not Applicable

Completed

• Conditions: Sarcopenia
• Interventions: Behavioral: Full body resistance training; Dietary Supplement: Peanut protein powder

• Registration Number: NCT04707963
• Lead Sponsor: Auburn University

Brief Summary

This study will evaluate the adaptations in skeletal muscle that occur in response to 10 weeks of weight training with or without peanut protein supplementation in untrained men and women ages 18-30

Detailed Description

This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in young adults who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 18-30 years (n=40), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=10 males, n=10 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=10 males, n=10 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.

Study Timeline

• Study First Submitted: 2021-01-10
• Study First Submitted QC: 2021-01-11
• Study First Posted: 2021-01-13
• Study Start: 2021-02-06
• Primary Completion: 2021-05-31
• Study Completion: 2021-05-31
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-08
• Last Update Posted: 2021-06-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• body mass index (body mass/height squared) less than 35 kg/m2
• resting blood pressure averaging less than 140/90 mmHg (with or without medication)

Exclusion Criteria

• known peanut allergy
• actively participating in resistance training for more than 2 days/week
• any known overt cardiovascular or metabolic disease
• metal implants that will interfere with x-ray procedures
• medically necessary radiation exposure in the last six months (except dental x-ray)
• any medical condition that would contradict participating in an exercise program, giving blood or donating a skeletal muscle biopsy (i.e. blood clotting disorder or taking blood thinners)
• pregnant or trying to become pregnant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Wait-list Control Group	Full body resistance training	Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
Immediate Intervention Group	Full body resistance training	Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
Immediate Intervention Group	Peanut protein powder	Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period

Primary Outcome Measures

Name	Time	Method
Change in acute myofibrillar protein synthesis rates	24 hours	Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise; Change in right leg vastus lateralis myofibrillar protein synthesis rates using the integrated deuterium oxide technique from biopsies immediately before and 24 hours after resistance exercise
Change in mid-thigh skeletal muscle area and quality	0-10 weeks	Peripheral quantitative computed tomography (pQCT) cross-sectional image of mid-right thigh assessed for overall muscle density (mg/cm\^3)

Secondary Outcome Measures

Name	Time	Method
Change in Type I and II Muscle Fiber Cross-Sectional Area	0-10 weeks	Muscle biopsy immunofluorescent staining for determination of type I and type II muscle fiber cross sectional area (fCSA) as a cellular determinant of skeletal muscle hypertrophy
Change in leg extensor isokinetic dynamometry	0-10 weeks	maximal isokinetic right leg extensions on an isokinetic dynamometer (BioDex)
Change in fecal microbiome composition	0-10 weeks	alpha- and beta-diversity of 16S bacterial rDNA
Change in appendicular lean mass	0-10 weeks	Change in lean mass (kg) of limbs as measured by dual energy x-ray absorptiometry (DXA)

Trial Locations

Locations (1)

Auburn University; 🇺🇸 Auburn, Alabama, United States